Marketed as Ozempic, Wegovy or Saxenda, these drugs are administered via a weekly injection that mimics GLP-1 - a hormone ...

LONDON – Doctors worldwide should diagnose obesity differently, relying on broader criteria and taking into account when the condition causes ill-health, according to a new framework drawn up by ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

This is just a glimpse of the insights available to CivicScience clients. Want to see the full picture? Let’s talk. As the ...

Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...

Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of ...

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that ...

The Dow, S&P 500, and Nasdaq are gaining Tuesday as the stock market digests a report on producer price inflation and rising bond yields.

Lilly revised its revenue guidance down 5%, to $13.5 billion, missing consensus of $14 billion by $500 million. But the guidance still represents a 45% increase from the same quarter in 2023. Lilly ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...